key: cord-0875194-jd78y4m0
authors: Merritt-Genore, HelenMari; Moosdorf, Rainer; Gillaspie, Erin; Lother, Sylvain; Engelman, Daniel; Ahmed, Shahnur; Baciewicz, Frank A.; Grant, Michael C.; Milewski, Rita; Cawcutt, Kelly; Hayanga, J Awori; Chatterjee, Subhasis; Arora, Rakesh C.
title: Perioperative Coronavirus Vaccination - Timing and Implications: A Guidance Document
date: 2021-08-08
journal: Ann Thorac Surg
DOI: 10.1016/j.athoracsur.2021.07.016
sha: cfff7155faa4354f3763660d849844cd9ec32966
doc_id: 875194
cord_uid: jd78y4m0

[Figure: see text]

The severe acute respiratory syndrome coronavirus-2 (SARS Cov-2) is responsible for the pandemic and has presented novel clinical challenges which must be navigated using current best evidence and clinical judgment. The approval of the first vaccinations in late 2020 provided a general sense of hope but raised questions regarding optimal timing of vaccination relative to major cardiac and thoracic surgeries.

Patients who require cardiothoracic surgery are at risk for adverse outcomes from COVID-19, as underlying cardiovascular disease and oncologic processes have each been identified as independent predictors of increased mortality (1) (2) (3) . The existence of comorbidities such as hypertension, diabetes, chronic lung conditions, and chronic kidney disease have also been recognized to increase COVID-19 severity (4) (5) (6) (7) (8) . The risk of thromboembolic events for patients undergoing surgery for malignant disease is significantly elevated and may be further exacerbated by concomitant COVID-19 infection (9) (10) .

Additionally, respiratory complications may slow the recovery of the cardiothoracic patient. The incidence of respiratory complications ranges from 4-8% for patients undergoing coronary bypass, and as high as 20-45% after esophagectomy (9, 11) . Systemic inflammatory response syndrome (SIRS) is a typical sequela of both extracorporeal circulation and the hyperimmune reaction during the critical phase of COVID infection. These responses show similar patterns, as recently demonstrated by an upregulation of Neutrophil Extracellular Traps (NETs), and may synergistically increase the effect, as well as foster increase in hypercoagulative status (12) (13) . The potential for hospitalized patients to acquire COVID-19 through nosocomial spread poses further risk (14) (15) . In a recent study of 71 patients undergoing transcatheter valve replacement, two patients acquired COVID-19 from an unknown source soon after As of the first week of July 2021 in the United States, approximately 58% of adults and 47% of the population for a total of 158 million people have been vaccinated according to the Center for Disease Control (CDC) (19) . Vaccination has proven highly effective at reducing COVID-19 transmission, and acquired immunity reduces infection severity, risk of hospitalization and of death for those that are infected with the virus (20) (21) (22) (23) (24) (25) . As mutations and variation in the original viral strain become more prevalent, vaccination dosing and potentially modification for protection may be required (26) .

The COVIDSurg Collaborative has advocated for the prioritization of surgical patients over the general population, to facilitate the reinstitution of elective surgery globally and also prevent COVID-19-related deaths in patients undergoing major surgery (27) . Various surgical societies have developed guidelines to guide peri-operative vaccination. The recent ACC Statement on Cardiovascular Disease

Considerations for COVID-19 Vaccine Prioritization identified patients with non-rate-controlled atrial fibrillation, those with an ICD or on antiarrhythmics to suppress ventricular arrhythmias, obstructive coronary artery disease, and those with heart failure as higher risk for adverse outcomes with COVID-19 (28) (29) (30) .

At the time of the drafting of this document, no formal guidelines exist regarding the timing of vaccine doses in relation to major cardiothoracic surgical procedures. To determine the optimal timing in cardiothoracic surgery patients, representatives from critical care, adult cardiac and thoracic surgery and infectious disease subspecialities have collaborated to provide a guidance statement based on currently available data. As with other guidance documents, it is acknowledged that much of the impact, risks and long-term sequelae of the pandemic, and of the vaccinations themselves, remain largely unknown. (21) (22) (23) (24) (25) 31) . One additional vaccine is currently in use in Europe, Canada, Asia and Latin America, and its U.S. EUA application is currently being prepared (31). See Table 1 given between four and twelve weeks after the first (22) . Similar to the AZD vaccine, the J&J vaccine was temporarily paused due to report of thrombotic events but following investigation the FDA and Center for Disease Control both recommended resumption of its administration (32) (33) .

The majority of side effects occur within 7 days of vaccine administration and are mild to moderate in severity ( Figure 1 ) (21) (22) (23) (24) (25) . Maximum efficacy was achieved at 2 weeks after the final vaccine dose.

J o u r n a l P r e -p r o o f Due to concern over supply shortages, adverse effects, variant mutations, and booster necessity, combination or "mixed" vaccine-series from different manufacturers have been considered and utilized in some scenarios. While antibody levels seem to be similar to homogenous vaccination, there has been concern for increase in adverse effects (34) (35) . The CDC presently does not support mixed-product series, as the efficacy and safety has not been fully evaluated (36) . Further trials are ongoing in this realm.

Although there is a paucity of high-quality data directly addressing vaccination in the perioperative period for cardiothoracic patients, the following recommendations are based on the best available evidence, including data from current and prior disease outbreaks and consensus opinion from experts. It is important to note that standard-grade recommendations were not utilized due to the limitations of data and nature of the changing landscape in this realm. The guidance statements thus fall into three modified categories as follows:

Recommended: The intervention is beneficial (strong recommendation) OR the intervention is a best practice statement.

Not Recommended: The intervention is not beneficial OR may be harmful.

OR exercise caution when considering this intervention.

It is not recommended to delay emergency surgery based on vaccination status.

Vaccination Prior to Elective Surgery:

1. We recommend that patients complete full vaccination series as early as possible before any elective surgical procedure that is not time sensitive. Clinical trials demonstrate maximum efficacy against COVID-19 occurs at least two weeks following complete vaccination.

2. For elective surgeries that are time-sensitive and cannot afford the completion of vaccination series, a single dose of vaccine as early as possible before surgery should be considered. Data demonstrates protection from infection beginning 14 days after the first dose.

3. Administering COVID-19 vaccines within a few days prior to surgery is not recommended as patients are unlikely to benefit immunologically, may have side effects mimicking infection, and side effects may be significant in some cases, and affect post-operative recovery.

regarding choice to receive or refuse vaccination is recommended for all patients prior to nonemergent surgery.

The suspension or delay of elective cases during the pandemic poses negative effects on health outcomes (37) (38) . Efforts should continue to assure the performance of safe and prompt surgery, regardless of vaccine status. However, there is data to support global vaccine prioritization for patients scheduled for elective surgery. The COVIDSurg Collaborative evaluated the number of patients needed to vaccinate pre-operatively to prevent one COVID-19 related death in 1 year. They enrolled 141,582 patients across 1667 hospitals in 116 countries and concluded that vaccination for elective surgery could prevent 56,687 COVID-related deaths (27) .

Although completion of both vaccine doses (mRNA) is most effective and is recommended, there is evidence that a single dose of vaccine is protective against "wild-type" COVID-19 to varying degrees, and that immunity will typically begin to develop approximately 10-14 days following the initial dose of mRNA and viral vector vaccines( Figure 1 ) (21) (22) (23) (24) . Therefore, if a vaccine is administered only a few days before surgery, patients are unlikely to reap the benefits in the immediate perioperative period. In general, the earlier the vaccine can be given preoperatively, the greater the protection (27) .

Reactogenicity refers to the subset of reactions that occur around the time of vaccination and represent a physical manifestation of the inflammatory response to vaccination (39) . Physicians should ensure vaccination reactogenicity has resolved and that any adverse event risk is minimal before proceeding with elective cases. Much of the data for these recommendations stems from childhood vaccine research. Current, recent, or upcoming surgery is not technically a contraindication to vaccination, but certain factors might lead a provider to consider these as a precaution (42) (43) .

J o u r n a l P r e -p r o o f 1. Recommend shared decision-making (between all providers and the patient) to develop personalized plan for future vaccination following cardiothoracic surgery.

2. In general, we recommend that patients recover from immediate major surgery and/or postoperative complications prior to vaccination. The rationale for this is two-fold: 1) to allow a robust immune response to vaccination and 2) to avoid a setback or confounding symptoms where there is potential overlap of vaccine adverse responses and manifestations of postoperative complications.

The resolution of the acute phase recovery may be confirmed by several criteria including: no persistent systemic inflammatory response, unremarkable wound healing, liberation from respiratory support, and undergoing a typical convalescence without active medical problems which may interfere with the vaccination effect or mimic side effects. Vaccination is thus not recommended for patients still in an intensive care unit or ward with active, acute medical problems; however, being in a skilled nursing facility is not a contraindication for vaccination. The convalescent time is not considered to be concrete and varies by individual patient and by procedure. For example, after an esophagectomy, patients have a median length of stay was 13 days with 25% of patients requiring discharge to institutional care facilities postoperatively, and a 18.2% readmission rate (44) . This is in distinction to data from patients undergoing coronary bypass surgery which suggests a more variable percentage of discharge to skilled (47) . Following the first vaccination the most common systemic symptoms were fatigue, headache and myalgia (ranging between 19-31% incidence). The second mRNA vaccination may manifest a higher reactogenicity with fatigue, headache, fever, chills and myalgias all common ranging between 25-54% in incidence. Specifically fever and chills occurred at 30% following the second vaccination (48) . Systemic adverse effects were also noted at similar incidences following viral vector vaccination (25) . Vaccination in the acute postoperative period may cause diagnostic confusion between manifestations of the underlying illness and possible adverse effects of vaccination or superimposing adverse effects of the vaccine on the underlying illness.

For instance, in an esophagectomy patient fever and malaise may indicate an anastomotic leak (present in between 6-11% of patients) (9) . Likewise, sternotomy patients may develop postoperative pneumonia or a deep sternal wound infection. In addition to creating a bit of a clinical conundrum, there is substantial cost and increased length of stay associated with the workup of postoperative fever (48) (49) .

As a counterpoint to the issue of investigation fever of unknown origin, timing of vaccination as it relates to the benefit to the patient and community as of a whole of viral infection spread will also need to be factored. At time of writing, there is still a lack of clarity from the World Health Organization (WHO) and CDC on appropriate recommendations in this regard. As such, individual institutions/heath system are relegated to determine this cost and risk/benefit ratio within the context of local COVID-19 burden. Prior vaccination initiatives for hospitalized patients (but not specifically cardiothoracic patients) for immunity against other illnesses (i.e.: influenza) have been successful. Data suggests that up to 70% of patients who were vaccinated during hospitalization demonstrate successful immune response (seroconversion and/or 4-fold or greater increase in antibodies to at least one influenza strain) (50), without increased risk of fever, evaluation for fever, outpatient visits or readmission within 7 days. This seems to suggest an J o u r n a l P r e -p r o o f adequate immune response to vaccination without increased risk of reactogenicity complicating the clinical picture. The influenza vaccination is also well-studied, and has been well-established regarding safety profile, while COVID vaccination was only recently developed and approved for emergency usage (21) (22) (23) (24) (25) however, given the differences between the influenza and COVID vaccines, this data must be interpreted and applied cautiously. The influenza vaccine is typically an inactivated viral vaccines or live attenuated vaccine and represents a different mechanism of action to the current COVID vaccines (mRNA and viral vector) (47) . Reactogenicity, specifically fever occurs less frequently following influenza vaccine versus COVID vaccine (1-3% versus 9-30%) (47) (48) (49) (50) (51) .

For all of these reasons, shared decision making suggested for vaccination timing postoperatively, considering each patient's observed and expected postoperative course, as well as short and long-term risks and benefits.

Recommend that all doses be administered as close to the recommended interval as possible; however, the second dose may be administered safely up to 42 days after the first dose when a delay is inevitable.

The CDC COVID-19 Vaccine Task Force recommends that all doses be administered as close to this interval as possible, however the second dose may be administered up to 42 days after the first dose when a delay cannot be avoided (52) . Regarding patients who undergo surgery between the first and second dose of an mRNA cycle, the CDC acknowledges a grace period for administration for the second vaccine dose. Pfizer-BioNTech recommends the second vaccination occurs between 21 days and 6 weeks, while

Moderna guidelines suggest between 28 days and 6 weeks is safe (52).

1. Recommend that surgery should be delayed if possible, during the period that a patient may be infectious.

The timing of elective surgery after recovery from COVID-19 uses both symptom-and severity-based categories, and ranges from 2 weeks for an asymptomatic patient to up to 12 weeks for patients who required care in the intensive care unit (50) . Further preoperative studies may be recommended to evaluate the patient's cardiopulmonary function, coagulation status, markers of inflammation, and nutritional status following COVID-19 illness, and if the patient experienced critical illness or prolonged symptoms, then considerations of surgical delays should incorporate the trajectory of the patient's recovery as well as the presence of new risk operative risk factors (53) .

Seroreversion and length of natural immunity appears to be related to the severity of illness, with more robust antibody presence in patients who were most ill, while up to 5-10% of individuals do not develop IgG antibodies after known infection (54) (55) (56) (57) (58) . Infection with SARS-CoV2 produces antibodies against specific antigens which target the nucleocapsid (N) protein and the spike (S) protein's S1 subunit and receptor binding domains (RBD). Antibody testing against N, S or RBD indicates a prior exposure to SARS-CoV-2. The CDC presently recommend vaccination for all persons with prior COVID-19 illness, as natural immunity seems to be more variable than protection from vaccination (52) . Complex understanding of antibodies and identification of best testing is rapidly expanding and will be of interest in future guidance documents. Patients should wait at least 14 days after COVID-19 diagnosis, and for complete resolution of their illness prior to getting their first vaccine dose.

It is important to note that patients who have previously been infected with COVID-19 seem to have higher systemic reactogenicity after the first vaccination (headache, fever, chills, muscle-pain etc.) than sero-negative patients (55) . Furthermore, there is ongoing investigation as to whether a single dose of vaccination is sufficient in patients with prior COVID-19 infection with present guidelines endorsing standard vaccination with recommended doses.

Due to associated comorbidities, monoclonal antibodies may have been administered to cardiothoracic surgery patients at the time of COVID-19 illness. If patients received these therapies, a period of 90 days should pass before vaccination based on CDC recommendations (52) . This is primarily to ensure that a robust immune response is achieved from the vaccine administration.

For patients who are to have thymectomy, have had thymectomy or otherwise have impairment of T-cell function (transplant recipients), response to the COVID-19 vaccine may be diminished (59) (60) . The CDC guidelines recommend vaccination of immunocompromised individuals despite uncertain efficacy of immunity compared to the general population (61) . Preoperative antibody testing in specific populations may be obtained to determine immunity and to plan for appropriate postoperative management (62) .

Convalescent plasma therapy has been well tolerated in this population and should be considered a treatment option should these patients develop a clinical course of COVID-19 after surgery (63) (64) (65) (66) .

Lastly, given the distinctive nature of pulmonary and cardiac transplant patients, the group defers to specific transplant societal recommendations regarding vaccination in these populations.

Vaccine induced immune thrombocytopenia (VITT) is a unique complication that is more prevalent with the viral vector as opposed to the mRNA vaccines. Considering important implications in the J o u r n a l P r e -p r o o f postoperative phase of cardiothoracic surgery, VITT will be further expanded here. The etiology is understood to be like heparin-induced thrombocytopenia (HIT) and leads to arterial and venous thrombosis. Cerebral sinus vein thrombosis is another even more rare, but serious complication occurring mainly but not exclusively in younger female patients between 10 -16 days post vaccination (32) . Cases were associated with thrombocytopenia, and platelet activating antibodies against platelet factor 4 (PF4), similar to heparin induced thrombocytopenia and thrombosis (HIT). One proposed mechanism involves "soluble spike protein variants," which can occur when a segment of introduced DNA from a viral vector is not transcribed optimally into the cell nucleus, and subsequently spliced into shorter protein variants, which are released as soluble spike protein variants (67) . The soluble spike protein variants may bind to the endothelial ACE receptors, like the SARS CoV 2 virus itself, and may thus mimic the endothelitis with prothrombotic effects, including a NET-reaction of neutrophils as part of the inflammatory process. While vaccination status should not factor into emergent or unavoidable surgical interventions, anticipating reactogenicity may be helpful. Patients in the acute phase of recovery from major cardiothoracic surgery may delay vaccination briefly to allow for a full immune response to the vaccine, and to avoid clinical confusion with regards to common systemic symptoms post-vaccination. As providers decide between vaccines during the perioperative period, consideration should be given to potential complications (including VITT), as well as dosing details, including the need to coordinate follow up appointments for second vaccine administration. The guidelines for vaccination timing now permit up to six weeks between a first and second dose of mRNA vaccines.

Patients with prior COVID-19 illness should still be vaccinated and may experience more reactogenicity after the initial dose of vaccine. Recently, new variants of SARS-Cov 2 have appeared, and protection against all strains from vaccination is presently undetermined. As providers decide between vaccines during the perioperative period, consideration should be given to potential complications, as well as dosing details, including the need to coordinate follow up appointments for second vaccine administration. Shared decision making between providers and patients, and awareness of the variants, regional conditions and infectious rates may guide the determination of vaccination type and timing.

The strength of the recommendations within this article are modified due to the limitations of data, and it is important to note that the guidance statements were formed based on existing information at the time of development. The authors acknowledge that new data are continually emerging regarding the COVID-19 pandemic and proffer this guidance document based on best current available knowledge. J o u r n a l P r e -p r o o f

Nosocomial infections in patients with cancer

Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer

Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 -Georgia

High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation

Prevalence and impact of diabetes among people infected with SARS-CoV-2

Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease

Complications of Esophageal Resection

2020. ebook.sts.org. Accessed

COVID-19 and Life Threatening Cardiac and Cerebellar Thromboembolic Events in Cardiac Operations

Postoperative Care of the Cardiac Surgical Patient

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Assessment of Neutrophil Extracellular Traps in Coronary Thrombus of a Case Series of Patients with COVID-19 and Myocardial Infarction

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Perioperative SARS-CoV-2 infections increase mortality, pulmonary complications, and thromboembolic events: a Dutch, multicenter, matchedcohort clinical study

Transcatheter aortic valve replacement during the COVID-19 pandemic-A Dutch single-center analysis

on behalf of The Society of Thoracic Surgeons COVID-19 Task Force. Adult Cardiac Surgery and the COVID-19 Pandemic: Aggressive Infection Mitigation Strategies Are Necessary in the Operating Room and Surgical Recovery

COPE Study Collaborators. Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial Study (COVID in Older PEople)

United States Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States

SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. Viruses

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Safety and Efficacy of a Single Dose of Ad26.Cov2. S Vaccine against Covid-19. NEJM

Effectiveness of covid-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. 14

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization

COVID-19, and inherited arrhythmia syndromes

Cardiac and arrhythmic complications in patients with COVID-19

Thrombotic Thrombocytopenia after ChAdOx1 nCOV-19 Vaccination. NEJM. 2021

United States Center for Disease Control and Prevention. CDC Recommends Use of Johnson and Johnson's Janssen COVID-19 Vaccine Resume

Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens

Heterologous primeboost COVID-19 vaccination: initial reactogenicity data

United States Center for Disease Control and Prevention. Pfizer-bioNTech COVID-19 Vaccine Questions

COVID-19 North American Cardiac Surgery Survey Working Group. Cardiac surgery in North America and coronavirus disease 2019 (COVID-19): Regional variability in burden and impact

Society of Thoracic Surgeons COVID-19 Task Force and the Workforce for Adult Cardiac and Vascular Surgery

The how's and what's of vaccine reactogenicity. NPJ Vaccines

Influence of anesthesia on immune responses and its effect on vaccination in children: review of evidence

Statement of the German Standing Committee on Vaccination at the RKI. Recommendations of the Standing Committee on Vaccination. (STIKO) at the Robert Koch Institute/Effective

Age-dependent variation of lymphocyte function in the postoperative child

Vaccination: is it a real problem for anesthesia and surgery?

Hospital Readmission Is Associated with Poor Survival After Esophagectomy for Esophageal Cancer

Coronary revascularization outcomes in relation to skilled nursing facility use following hospital discharge

Early discharge after coronary artery bypass graft surgery: Are patients really going home earlier? JTCVS

Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines

Evaluation of postoperative fever: Usefulness and costeffectiveness of routine workup

Cost and Effectiveness of Postoperative Fever Diagnostic Evaluation in Total Joint Arthroplasty Patients

Hospitalization is an Underutilized Opportunity to Vaccinate for Influenza

Adverse reactions to influenza vaccine in elderly people: randomized double-blind placebo-controlled trial

United States Centers for Disease Control and Prevention. Frequently Asked Questions About COVID-19 Vaccination

Preparing previously COVID-19-positive patients for elective surgery: a framework for preoperative evaluation

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Evolution of antibody immunity to SARS-CoV-2

Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep

Differences in antibody kinetics and functionality between severe and mild severe acute respiratory syndrome coronavirus 2 infections

The role of the thymus in COVID-19 disease severity: implications for antibody treatment and immunization

Updated healthcare infection prevention and control recommendations in response to COVID-19 vaccination

Testing recommendation for COVID-19 (SARS-CoV-2) in patients planned for surgery -continuing the service and 'suppressing' the pandemic

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Effectiveness of Convalescent Plasma Therapy in the Treatment of Moderate to Severe COVID 19 Patients: A Systematic Review and Meta-Analysis

Syndrome:Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vectorbased vaccines

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Workforce on Critical Care, which focuses on the identification and assessment of issues of concern to surgeons who perform critical care. The authors would like to acknowledge the STS Workforces on Adult Cardiac and Vascular Surgery and General Thoracic Surgery for their review and support of this work.